Alerts will be sent to your verified email
Verify EmailLAURUSLABS
Laurus Labs
|
Neuland Laboratories
|
Alivus Life Sciences
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in Canada
|
23.0 | n/a | n/a |
Number of ANDA's Filed in Europe
|
22.0 | n/a | n/a |
Number of ANDA's Approved in Europe
|
19.0 | n/a | n/a |
Number of ANDA's Filed in USA
|
43.0 . | n/a | n/a |
Number of ANDA's Approved By USFDA
|
35.0 . | n/a | n/a |
Number of ANDA's Approved by Canada
|
16.0 | n/a | n/a |
US DMF Filings
|
90.0 . | 72.0 . | 561.0 . |
R&D as a % of Total Sales
|
4.6 % | 4.15 % | 3.4 % |
Financials
|
|||
5 yr Average ROE
|
18.77 % | 14.95 % | 37.41 % |
5yr average Equity Multiplier
|
2.06 | 1.56 | 2.33 |
5yr Average Asset Turnover Ratio
|
0.71 | 0.74 | 0.76 |
5yr Avg Net Profit Margin
|
11.95 % | 13.18 % | 20.19 % |
Price to Book
|
10.24 | 10.97 | 4.36 |
P/E
|
89.97 | 95.0 | 24.77 |
5yr Avg Cash Conversion Cycle
|
91.73 Days | 38.21 Days | 76.63 Days |
Inventory Days
|
114.71 Days | 87.5 Days | 93.94 Days |
Days Receivable
|
120.6 Days | 85.17 Days | 125.3 Days |
Days Payable
|
145.16 Days | 118.14 Days | 114.87 Days |
5yr Average Interest Coverage Ratio
|
8.98 | 20.78 | 320.13 |
5yr Avg ROCE
|
22.73 % | 17.63 % | 51.63 % |
5yr Avg Operating Profit Margin
|
24.36 % | 21.01 % | 30.06 % |
5 yr average Debt to Equity
|
0.56 | 0.15 | 0.0 |
5yr CAGR Net Profit
|
-18.29 % | 26.4 % | 8.5 % |
5yr Average Return on Assets
|
8.99 % | 9.87 % | 15.32 % |
Shareholdings
|
|||
Promoter Holding
|
27.59 % | 32.68 % | 74.94 % |
Share Pledged by Promoters
|
2.69 % | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
0.32 % | -3.54 % | -7.91 % |
Change in Mutual Fund Holding (3 Yrs)
|
3.01 % | 6.87 % | 3.35 % |
Laurus Labs
|
Neuland Laboratories
|
Alivus Life Sciences
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|